Manipulating selectivity through gatekeeper interactions: Inhibition of EGFR and its T790M mutant

被引：0

作者：

Hanan, Emily ^{[1
]}

Bryan, Marian ^{[1
]}

Burdick, Daniel ^{[1
]}

Chan, Bryan ^{[1
]}

Chen, Yuan ^{[1
]}

Eigenbrot, Charles ^{[1
]}

Heald, Robert ^{[2
]}

Heffron, Timothy ^{[1
]}

La, Hank ^{[1
]}

Purkey, Hans ^{[1
]}

Schaefer, Gabriele ^{[1
]}

Schmidt, Stephen ^{[1
]}

Seward, Eileen ^{[2
]}

Sideris, Steve ^{[1
]}

Wang, Shumei ^{[1
]}

Yu, Christine ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

[2] Discovery Charles River, Harlow, Essex, England

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 252卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

620

引用

页数：1

共 50 条

[31] Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Yong
Yun, Cai-Hong
Park, Eunyoung
Rcan, Dalia E.
Manuia, Mari
Juarez, Jose
Xu, Chunxiao
Rhee, Kevin
Chen, Ting
Zhang, Haikuo
Palakurthi, Sangeetha
Jang, Jaebong
Lelais, Gerald
DiDonato, Michael
Bursulaya, Badry
Michellys, Pierre-Yves
Epple, Robert
Marsilje, Thomas H.
McNeill, Matthew
Lu, Wenshuo
Harris, Jennifer
Bender, Steven
Wong, Kwok-Kin
Janne, Pasi A.
Eck, Michael J.
NATURE, 2016, 534 (7605) : 129 - +
[32] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Skoulidis, Ferdinandos
Papadimitrakopoulou, Vassiliki A.
CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
[33] Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation
Ma, W.
Gong, J.
Shan, J.
Lewis, D.
Xiao, W.
Hung, J.
Moore, E. H.
Zhang, Y.
Mans, N. Z.
Welborn, J.
Lam, K. S.
Li, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1863 - S1864
[34] Discovery of a potent dual ALK and EGFR T790M inhibitor
Jang, Jaebong
Son, Jung Beom
To, Ciric
Bahcall, Magda
Kim, So Young
Kang, Seock Yong
Mushajiang, Mierzhati
Lee, Younho
Janne, Pasi A.
Choi, Hwan Geun
Gray, Nathanael S.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 136 : 497 - 510
[35] GefitinibDevelopment of resistant EGFR T790M mutation: case report
Reactions Weekly, 2016, 1593 (1) : 91 - 91
[36] Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia
Cai-Hong Yun
Eunyoung Park
Dalia Ercan
Mari Manuia
Jose Juarez
Chunxiao Xu
Kevin Rhee
Ting Chen
Haikuo Zhang
Sangeetha Palakurthi
Jaebong Jang
Gerald Lelais
Michael DiDonato
Badry Bursulaya
Pierre-Yves Michellys
Robert Epple
Thomas H. Marsilje
Matthew McNeill
Wenshuo Lu
Jennifer Harris
Steven Bender
Kwok-Kin Wong
Pasi A. Jänne
Michael J. Eck
Nature, 2016, 534 : 129 - 132
[37] The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
Tseng, Jeng-Sen
Su, Kang-Yi
Yang, Tsung-Ying
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Chen, Hsuan-Yu
Tsai, Chi-Ren
Yu, Sung-Liang
Chang, Gee-Chen
ONCOTARGET, 2016, 7 (30) : 48059 - 48069
[38] Investigating the Selectivity of Allosteric Inhibitors for Mutant T790M EGFR over Wild Type Using Molecular Dynamics and Binding Free Energy Calculations
Tinivella, Annachiara
Rastelli, Giulio
ACS OMEGA, 2018, 3 (12): : 16556 - 16562
[39] QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
Fatima, Shehnaz
Pal, Divyani
Agarwal, Subhash Mohan
CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 94 (01) : 1306 - 1315
[40] Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M
Soucheray, Margaret
Capelletti, Marzia
Pulido, Ines
Kuang, Yunan
Paweletz, Cloud P.
Becker, Jeffrey H.
Kikuchi, Eiki
Xu, Chunxiao
Patel, Tarun B.
Al-shahrour, Fatima
Carretero, Julian
Wong, Kwok-Kin
Janne, Pasi A.
Shapiro, Geoffrey I.
Shimamura, Takeshi
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →